Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of RO4607381 in Patients with Coronary Heart Disease or CHD Risk Equivalent
2005-002910-39Phase 2Completed
- Sponsor
- Roche
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronary arteriosclerosis comparing RO4607381 + atorvastatin with Placebo + atorvastatin (2 arms). Primary endpoint: HDL-C change at 24 weeks. Started Sep 2006; status: completed.
02
Drugs
dalcetrapib
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2005-002910-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002910-39.